Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02421588 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
A Phase 3 study, sponsored by PharmaMar.
- Completed
- Registry status
- Phase 3
- Development phase
- 442
- Enrollment target
NCT02421588 is a Phase 3 study that has completed, run by PharmaMar. The registered enrollment target is 442 participants.
The verdict
NCT02421588, a Phase 3 study, has completed, sponsored by PharmaMar.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 442 participants
- Enrollment target
Study Summary
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate the activity and safety of PM01183 versus PLD or topotecan as control arm in patients with platinum-resistant ovarian cancer. PM01183 will be explored as single agent in the experimental arm (Arm A) versus PLD or topotecan in the control arm (Arm B).
Interventions
- DRUG Topotecan
- DRUG Pegylated liposomal doxorubicin (PLD)
- DRUG Lurbinectedin (PM01183)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 442 participants |
| Start Date | 2015-05 |
| Est. Completion | 2018-10-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02421588
The ClinicalTrials.gov registry entry for NCT02421588 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 442 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Topotecan is the first listed.
NCT02421588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02421588 about?
NCT02421588 is a clinical study titled "Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients". Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate the activity and safety of PM01183 versus PLD or topotecan as control arm in patients with platinum-resistant ovarian cancer. PM01183 will be explored as single agent in the experimental arm (Arm A) versus PLD or to...
What is the current status of trial NCT02421588?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 442 participants. The study started on 2015-05. Estimated completion is 2018-10-12.
What interventions are being tested in trial NCT02421588?
The interventions under investigation include: Topotecan (DRUG), Pegylated liposomal doxorubicin (PLD) (DRUG), Lurbinectedin (PM01183) (DRUG).
Who is sponsoring clinical trial NCT02421588?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.